{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-18T02:56:20.108Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-18. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-18. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-18, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"NTLA\",\n  \"company\": \"Intellia Therapeutics, Inc.\",\n  \"investigation_summary\": \"Intellia is a clinical-stage CRISPR gene-editing biotech whose lead candidate lonvo-z (formerly NTLA-2002) for hereditary angioedema produced exceptional Phase 3 HAELO data in June 2026 — an 89% reduction in on-demand-treated attacks and 91% reduction in moderate/severe attacks versus placebo, with zero serious adverse events. The rolling BLA was initiated April 2026 with anticipated US approval/launch in H1 2027. Smart money is ABSENT: all recent Form 4 transactions were RSU/option grants to directors at $0 cost basis (code A), not open-market cash purchases. Stock has run from ~$8 lows (November 2025) to ~$15 post-catalyst, still well below the year-high of $28 and analyst mean target of $27. Options flow is strongly bullish with 76% net call directional bias. The core tension: a genuine high-probability regulatory catalyst exists in a 6-12 month window, but zero insider buying signal tempers conviction.\",\n  \"verdict\": \"promising\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"long_stock\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Intellia Therapeutics is a Cambridge-based CRISPR gene-editing platform company with two lead clinical programs: lonvo-z (formerly NTLA-2002) for hereditary angioedema and nexiguran ziclumeran for transthyretin amyloidosis. Lonvo-z targets the KLKB1 gene via in vivo CRISPR editing to permanently reduce plasma kallikrein, offering a potential one-time curative treatment vs chronic prophylaxis with injectables (e.g., Takeda's Takhzyro at ~$500K/year). The Phase 3 HAELO trial enrolled 80 HAE patients globally; lonvo-z showed durable attack reductions through data cutoff (~16 months post-infusion) and all secondary endpoints were statistically significant. Management initiated a rolling BLA submission in April 2026 — ahead of schedule relative to prior guidance. NTLA is pre-revenue, cash-burning (~$363M operating cash outflow in FY25), with $376M cash at end of Q1 2026 and no near-term debt maturities. Regeneron collaboration provides non-dilutive funding on select programs.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [],\n      \"insider_open_market_total_usd_90d\": 0,\n      \"distinct_insider_buyers_90d\": 0,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 0,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-06\",\n      \"recent_eps_surprise_pattern\": \"4 consecutive positive EPS surprises: Q1 2026 -9.8%, Q4 2025 -13.7%, Q3 2025 -7.8%, Q2 2025 -2.5%. Trend is improving (less negative surprise each quarter).\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"product\",\n          \"description\": \"HAELO Phase 3 lonvo-z data: 89% reduction in on-demand-treated attacks, 91% reduction in moderate/severe attacks; NEJM publication simultaneous with EAACI 2026 presentation. BLA rolling submission initiated April 2026.\",\n          \"date_or_window\": \"April 2026 (BLA start) through H1 2027 (anticipated approval/launch)\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"Rolling BLA review timeline; FDA acceptance of filing is the key next catalyst within 60 days of submission completion.\",\n          \"date_or_window\": \"Q3-Q4 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"product\",\n          \"description\": \"nexiguran ziclumeran (NTLA-2001) for ATTR amyloidosis — Phase 3 MAGNITUDE trial ongoing; readout timeline TBD but represents a second pipeline catalyst.\",\n          \"date_or_window\": \"H2 2026 / 2027\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": null,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -4.225,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": null,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"NTLA trades at ~$15 with analyst target of $27; stock is 47% below its 52-week high of $28 and 44% below mean analyst price target. With a potential BLA approval for lonvo-z in H1 2027 (first CRISPR therapy for HAE, addressable market >$3B), the current valuation does not appear to fully price in regulatory success given historical biotech re-rating patterns post-approval. However, cash runway concerns and ongoing dilution risk from ATM offerings create a ceiling on pure long equity upside.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"B+\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": true,\n      \"rsi_14\": 59.7,\n      \"macd_recent_bullish_cross\": true,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 15.2,\n    \"ytd_return_pct\": -40.3,\n    \"from_52w_high_pct\": 46.2\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-13\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm\",\n      \"key_takeaways\": [\n        \"HAELO Phase 3 secondary endpoints: lonvo-z arm (N=52) vs placebo (N=28): 89% reduction in monthly on-demand-treated attacks, 91% reduction in moderate/severe attacks; quality of life improvement -17.04 points (p<0.0001); all TEAEs mild/moderate with zero serious adverse events in lonvo-z arm; rolling BLA initiated April 2026; expected US approval/launch H1 2027\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-09\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/ntla-20260609.htm\",\n      \"key_takeaways\": [\n        \"Annual meeting: director elections passed; Deloitte & Touche reappointed as auditor; executive compensation approved (44.8M for vs 13.8M against) — minor dissent on say-on-pay but overall clean\"\n      ]\n    },\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY2025: operating cash outflows of $363M; total cash and equivalents $376M at Dec 31, 2025; ATM offering active (Amended 2022 Sales Agreement); Regeneron collaboration ongoing with amendment extending technology partnership through 2030; Nex-Z (ATTR amyloidosis) Phase 3 MAGNITUDE trial enrolling; lonvo-z BLA-enabling studies underway; NOL carryforwards indefinitely available\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-11\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026: operating cash outflow $82.5M (vs $79M Q1 2025); total cash $376M at Mar 31, 2026; revenue from Regeneron collaboration recognition; shares outstanding ~120.4M at Q1 close; current ratio 6.1x — strong liquidity position\"\n      ]\n    },\n    {\n      \"form\": \"Form 4\",\n      \"filed\": \"2026-06-10\",\n      \"url\": \"multiple director grants\",\n      \"key_takeaways\": [\n        \"June 9, 2026: directors Keresty (Georgia), Cohen (Fred E.), and Goff (Brian) each received RSU awards of 9,200 shares + stock options for 13,300 shares at $12.89 exercise price — all code A (grant/award, not open-market purchase). ZERO open-market cash purchases by insiders in the trailing period.\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-09-18\",\n      \"2026-07-17\"\n    ],\n    \"iv_summary\": \"ATM IV ~101% at Sep 18 expiry; OTM calls (17 strike) at $1.93 mid with IV 85%, still elevated vs pre-news levels (~70%); put/call ratio extremely low at 0.26 — aggressive call demand suggests bullish speculative positioning\",\n    \"notable_skew_or_flow\": \"Sep 18, 2026: net dollar bias +$177K (76% call-skewed); top OI on calls at $17 strike (1,748 contracts) and $15 ATM (704). Top OI on puts at $12 strike (2,143 — downside hedge built). V/OI not available for detailed whale block detection in current feed. High IV environment creates premium selling opportunity.\"\n  },\n  \"competitive_landscape\": \"HAE market dominated by Takeda's Takhzyro (lanadelumab, ~$500K/year, chronic subcutaneous injection every 2 weeks) and BioCryst's Orladevo (berinert alternatives). Ionis/ AstraZeneca also have HAE programs. Lonvo-z's value proposition: ONE-TIME CRISPR infusion vs lifelong chronic prophylaxis — major quality-of-life and payer economics advantage if durable response holds. CSL's Garadacord is another chronic therapy competitor. Intellia's key differentiation is the in vivo gene-editing mechanism that permanently knocks down KLKB1 rather than antibody neutralization.\",\n  \"key_risks\": [\n    \"No open-market insider buying reduces smart-money signal confidence — insiders received equity grants, not purchasing\",\n    \"Cash runway: ~$376M at Q1 2026 vs $363M annual burn rate implies <12 months of cash; ATM offerings likely before BLA approval creates dilution risk\",\n    \"Stock ran +23% on June 16 data print and now trades near $15 — significant portion of Phase 3 success may already be priced in\",\n    \"FDA review timeline: rolling submission initiated April, not yet accepted/fee paid — filing acceptance is a necessary catalyst within Q3 2026\",\n    \"Regulatory risk: FDA could request additional studies or impose REMS restrictions; CRL would obliterate the thesis\",\n    \"Competitive: Takeda and BioCryst have entrenched payer relationships; market access/launch execution will determine commercial trajectory\",\n    \"Technical: stock is already up ~90% from November 2025 lows — momentum is strong but entry price matters enormously for risk/reward\"\n  ],\n  \"what_the_market_might_be_missing\": \"The BLA rolling submission was initiated in April 2026 — earlier than previously guided, suggesting confidence in the filing quality. The June HAELO data showed durability through ~16 months (data cutoff) with all patients responding and stable plasma kallikrein suppression. If FDA accepts the filing within 60-90 days of completion (~mid-2026), that acceptance event alone could re-rate the stock toward $20+ given biotech historical patterns where regulatory submission acceptance triggers a 30-50% rerating for late-stage assets. The analyst target of $27 (vs current ~$15) implies near-doubling on approval — and the options market IV of ~100% is pricing in significant binary risk, creating an edge for structured plays that capture vega collapse post-adjudication.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"low_liquidity\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"8-K Jun 13 2026 - Phase 3 HAELO data\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm\"\n    },\n    {\n      \"label\": \"10-K FY2025 filed Feb 26, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526076550/ntla-20251231.htm\"\n    },\n    {\n      \"label\": \"10-Q Q1 2026 filed May 11, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm\"\n    },\n    {\n      \"label\": \"Form 4 - Keresty director grant Jun 9, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266241/xslF345X06/ownership.xml\"\n    },\n    {\n      \"label\": \"Form 4 - Cohen director grant Jun 9, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526266233/xslF345X06/ownership.xml\"\n    },\n    {\n      \"label\": \"Form 4 - Goff director grant Jun 9, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/ntla-20260609.htm\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-18T02:57:35.121Z",
      "raw_content": "<think>The dossier is for Intellia Therapeutics (NTLA), a clinical-stage CRISPR gene-editing biotech.\nKey facts:\n- Stock price: ~$15.20\n- Market cap: Not explicitly given, but shares outstanding ~120.4M -> ~$1.83B. This falls into \"asymmetric\" risk class (≤ $5B).\n- Catalyst: Phase 3 HAELO data for lonvo-z was exceptional (89% reduction in attacks, zero SAEs). Rolling BLA initiated April 2026. Anticipated US approval/launch H1 2027.\n- Smart Money: ZERO open-market insider buying. All Form 4s are RSU/option grants.\n- Options Flow: Strongly bullish (76% call bias), but IV is extremely high (~101% ATM).\n- Mispricing: Analyst target $27, stock at $15. 47% below 52w high.\n- Quality: Pre-revenue, cash-burning ($363M FY25 burn), $376M cash. Balance sheet grade B+.\n- Technical: Above 50DMA and 200DMA. RSI 59.7. MACD bullish cross.\n- Anti-signals: \"dilution\", \"low_liquidity\".\n- Scout verdict: \"promising\" (long_stock | csp).\n- Structure hints: long_stock, csp.\n\nLet's score according to the rubric:\nA. SMART-MONEY CLUSTER (max 25): 0 pts. No insider buys. 0 distinct buyers.\nB. OPTIONS FLOW / UOA (max 10): 3 pts. Bullish IV skew (call IV > put IV) consistent with thesis? IV is 101%, call demand is high. Let's give 2 pts for net_dollar_bias_pct > 30 (76% call skewed). 1 pt for OI building. Total: 3.\nC. CATALYST (max 25): 8 pts for pending product launch / FDA / contract milestone in horizon (BLA rolling, H1 2027 approval). 5 pts for quantifiable sector tailwind? Not really. Let's stick with 8. Total: 8.\nD. MISPRICING (max 15): 0 pts. Forward P/E null, EV/EBITDA negative, FCF yield null, SOTP gap null. Narrative says it's below analyst target but it's a pre-revenue biotech, so traditional multiples don't apply. 0.\nE. QUALITY (max 15): 0 pts. ROIC null, gross margin null, net debt/EBITDA null. Pre-revenue, cash burn. 0.\nF. MOMENTUM/TECHNICAL (max 10): 3 pts (above 50DMA and 200DMA). 2 pts (RSI 40-65). 1 pt (MACD bullish cross). Total: 6.\n\nTotal Score: 0 + 3 + 8 + 0 + 0 + 6 = 17.\nWait, let's re-evaluate Catalyst. \"pending product launch / FDA / contract milestone in horizon\" -> 8 pts.\nTotal is 17. This is well below 45.\nAnti-signals present: \"dilution\", \"low_liquidity\".\nRisk class: asymmetric (market cap ~$1.8B < $5B).\nThresholds for asymmetric: <45 Skip.\n\nLet's check the anti-signal gates:\n\"dilution\" -> ATM offering active, cash burn $363M vs $376M cash. Dilution risk is high.\n\"low_liquidity\" -> Avg daily volume < $5M? The dossier says \"low_liquidity\" in anti_signals_present. I must treat it as a gate.\nAlso, the score is 17. Definitely skip.\n\nReason for skip: Score is 17 (<45 threshold for asymmetric biotech). Zero insider buying, no traditional valuation metrics, high dilution risk from active ATM offerings, and low liquidity flags present. The dossier lacks the necessary smart-money confirmation and financial quality to justify a publication or paper-track.\n\nLet's compute score breakdown precisely:\nsmart_money: 0\noptions_flow: 3 (bullish skew + OI building)\ncatalyst: 8 (BLA initiation + Phase 3 data)\nmispricing: 0\nquality: 0\ntechnical: 6\nTotal: 17.\n\nCheck thresholds: <45 Skip.\nOutput format:\n{\n  \"skip\": true,\n  \"score\": 17,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 3,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score of 17 falls well below the 45 threshold for asymmetric risk class. The dossier shows zero insider buying, lacks traditional valuation metrics for a pre-revenue biotech, flags active dilution and low liquidity, and relies entirely on an unproven regulatory catalyst without the financial quality or smart-money confirmation required to clear the publication bar.\"\n}\n\nWait, should I give options_flow more points? \"4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish and flow_strength ∈ {moderate, strong}\" - dossier says \"net dollar bias +$177K (76% call-skewed); top OI on calls at $17 strike...\". Doesn't explicitly say whale_call_blocks_otm ≥ 2. I'll stick with 2 or 3. Let's give 3.\nTechnical: 3 (above 50/200DMA) + 2 (RSI 40-65) + 1 (MACD cross) = 6.\nCatalyst: 8.\nTotal 17.\n\nCheck anti-signal gate: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nDilution: ATM offering active, cash burn exceeds cash runway. Applies.\nLow liquidity: Flagged. Applies.\nSo skip is mandatory.\n\nI will formulate the JSON exactly as requested.\nDouble check the score calculation:\nA: 0\nB: 3\nC: 8\nD: 0\nE: 0\nF: 6\nSum: 17.\nMatches threshold rules.\nOutput matches schema.\nReady. \nOne minor thing: The prompt says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". Here selling is 0, buying is 0. So 0.\nOptions flow: \"3 pts: bullish IV skew (call IV > put IV) consistent with thesis\" + \"1 pt: large OI building at a defended price level\" = 4. I'll adjust to 4.\nTechnical: 3+2+1 = 6.\nCatalyst: 8.\nTotal: 18. Still <45.\nI will output the JSON. \nAll constraints met.\nProceed. \nOutput matches exactly. \nNo extra text.\nDone. \nLet's generate. \n```json\n{\n  \"skip\": true,\n  \"score\": 18,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 4,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score of 18 falls well below the 45 threshold for the asymmetric risk class. The dossier flags active dilution and low liquidity anti-signals that cannot be dismissed, shows zero open-market insider buying, and lacks traditional financial quality metrics for a pre-revenue biotech. The thesis relies entirely on an unproven regulatory catalyst without the smart-money confirmation or valuation anchor required to clear the publication bar.\"\n}\n```\nWait, let's verify the options flow scoring: \n\"4 pts: whale_call_blocks_otm ≥ 2...\" -> Not explicitly met. \n\"3 pts: bullish IV skew...\" -> IV is 101% ATM, call demand high. I'll give 3.\n\"2 pts: net_dollar_bias_pct > 30\" -> 76% call skewed. I'll give 2.\n\"1 pt: large OI building...\" -> Top OI at $17 and $15. I'll give 1.\nTotal options flow: 6.\nTechnical: 3+2+1 = 6.\nCatalyst: 8.\nTotal: 20. Still <45.\nI'll stick with 18 or 20. It doesn't change the outcome. I'll use 18 to be conservative.\nActually, the prompt says \"Cap at 10\" for options flow. So max 10. I'll give 4.\nI will output exactly as formulated.\nAll good. \nProceeds. \nOutput matches request. \nDone. \n[Self-Correction/Verification during thought]\nCheck risk class: market_cap not given explicitly, but shares outstanding ~120.4M * $15.2 ≈ $1.83B. ≤ $5B -> asymmetric.\nThreshold for asymmetric <45 -> Skip.\nAnti-signals: dilution, low_liquidity. Both apply.\nResult: Skip.\nJSON structure matches exactly.\nReady. \nOutput generation. \n(Note: I will ensure the JSON is strictly valid and contains no markdown fences as per \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\")\nProceeds. \n[Output Generation] -> *Self-Correction/Refinement during generation prep*: I will make sure the JSON keys and structure exactly match the prompt's skip schema.\n```json\n{\n  \"skip\": true,\n  \"score\": 18,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 4,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score of 18 falls well below the 45 threshold for the asymmetric risk class. The dossier flags active dilution and low liquidity anti-signals that cannot be dismissed, shows zero open-market insider buying, and lacks traditional financial quality metrics for a pre-revenue biotech. The thesis relies entirely on an unproven regulatory catalyst without the smart-money confirmation or valuation anchor required to clear the publication bar.\"\n}\n```\nMatches perfectly. Output matches. \nProceeds. \n[Final Check of the Prompt]\n\"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\"\nI will output raw JSON.\nDone. \n[Output Generation] (proceeds)\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 18,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 4,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score of 18 falls well below the 45 threshold for the asymmetric risk class. The dossier flags active dilution and low liquidity anti-signals that cannot be dismissed, shows zero open-market insider buying, and lacks traditional financial quality metrics for a pre-revenue biotech. The thesis relies entirely on an unproven regulatory catalyst without the smart-money confirmation or valuation anchor required to clear the publication bar.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 18,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 4,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score of 18 falls well below the 45 threshold for the asymmetric risk class. The dossier flags active dilution and low liquidity anti-signals that cannot be dismissed, shows zero open-market insider buying, and lacks traditional financial quality metrics for a pre-revenue biotech. The thesis relies entirely on an unproven regulatory catalyst without the smart-money confirmation or valuation anchor required to clear the publication bar.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 18,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 4,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 6\n  },\n  \"reason\": \"Score of 18 falls well below the 45 threshold for the asymmetric risk class. The dossier flags active dilution and low liquidity anti-signals that cannot be dismissed, shows zero open-market insider buying, and lacks traditional financial quality metrics for a pre-revenue biotech. The thesis relies entirely on an unproven regulatory catalyst without the smart-money confirmation or valuation anchor required to clear the publication bar.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 75013,
  "stop_reason": "stop",
  "completed_at": "2026-06-18T02:57:35.121Z"
}